Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Omnicell, Inc. filings on SEC EDGAR ↗
Omnicell reported total revenues of $929.9 million for the nine months ended September 30, 2026, a significant increase from $870.9 million in the prior year period. Net income for the same period rose sharply to $46.7 million compared to $4.1 million in 2025, driven by improved gross margins and controlled operating expenses.
Omnicell reported third quarter 2026 financial results with revenue of $308 million and GAAP net income of $11 million, both exceeding the high end of previous guidance. The company highlighted strong momentum for its next-generation Titan XT and OmniSphere platforms as healthcare providers prioritize medication management efficiency.
“We delivered solid third quarter results and continued to execute against our strategic priorities. We believe our performance reflects the discipline we have built into the business throughout the year, combined with continued customer interest in solutions that are designed to improve efficiency, safety, and workforce productivity across medication management.”
Randall A. Lipps, chairman, chief executive officer, and founder of Omnicell
“At the same time, we continue to see strong momentum with our next-generation platform, backed by a growing pipeline. Customers are validating the potential value of combining Titan XT with OmniSphere, our cloud-native platform, intended to improve productivity, efficiency, and workflow reliability.”
Randall A. Lipps, chairman, chief executive officer, and founder of Omnicell